Zoetis (ZTS) | Stock Overview & Key Data
Zoetis Performance Comparison
Stock Range
Today's Range
Low: $164.23
High: $167.36
on June 20, 2025
52 Week Range
Low: $139.70
High: $200.33
on April 9, 2025
on September 19, 2024
All-Time High: $249.27 on December 27, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$65.3B
EPS
5.81
P/E Ratio (TTM)
25.36
Forward P/E
23.24
P/B Ratio
13.14
PEG Ratio
23.24
Div. Yield
1.11%
ROE
52.77%
Beta
0.884
Debt to Equity
137.01
Financial Highlights
Profitability
Gross Margin
73.62%
Operating Margin
40.20%
Profit Margin
27.83%
Returns and Earnings
Return on Assets (TTM)
15.37%
Return on Equity (TTM)
52.77%
EBITDA
$4.1B
Net Income (TTM)
$2.6B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$20.93
Quarterly Revenue Growth (YoY)
4.20%
Quarterly Earnings Growth (YoY)
15.10%
Dividend Information
Last 12-Month Dividend
$1.86
Current Dividend Yield
1.11%
3-Year Average Dividend Yield
0.24%
3-Year Average Annual Dividend
$1.63
3-Year Total Dividends
$4.90
Ex-Dividend Date
April 21, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Zoetis ZTS | 65.30B Large-cap | 4.59% | 0.82% | -3.89% | -1.51% | -5.23% | -16.11% | -9.09% | -2.69% |
| Haleon Plc - ADR HLN | 43.57B Large-cap | 1.15% | -0.82% | -9.56% | -3.40% | 2.22% | -0.31% | 61.37% | 30.23% |
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 81.59% | 56.54% | 92.68% | 104.13% | 700.67% |
| United Therapeutics UTHR | 13.63B Large-cap | 3.86% | 6.78% | 3.03% | -16.01% | -13.07% | -2.45% | 39.52% | 191.96% |
| Neurocrine NBIX | 13.05B Large-cap | 6.31% | 1.26% | 10.50% | 16.61% | -3.60% | -8.35% | 24.21% | 17.50% |
| Viatris VTRS | 12.46B Large-cap | 9.38% | 18.81% | 20.71% | -2.30% | -14.57% | -9.01% | 0.38% | -33.65% |
Ownership & Short Interest
Insider Ownership
0.09%
Institutional Ownership
98.00%
Shares Short
8M
Short Ratio
2.67
Short % of Shares Outstanding
1.76%
Average 10-Day Volume
4M
Average 90-Day Volume
3M
Zoetis Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Zoetis would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ZTS's 52-week high and low?
- In the last 52 weeks, Zoetis reached a high of $200.33 (on September 19, 2024) and a low of $139.70 (on April 9, 2025).
- What is the market cap and P/E ratio for ZTS?
- Curious about Zoetis's size and valuation? Its market capitalization stands at 65.30B. When it comes to valuation, the P/E ratio (trailing twelve months) is 25.36, and the forward P/E (looking ahead) is 23.24.
- Does ZTS pay dividends? If so, what's the yield?
- Yes, Zoetis is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 1.11%, and the company has paid an average of $1.63 per share annually over the past 3 years.
- Who are Zoetis's main competitors or similar companies to consider before investing?
When looking at Zoetis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Haleon Plc - ADR
HLN43.57B Healthcare Drug Manufacturers - Specialty & Generic -0.31% 61.37% Intra-Cellular
ITCI14.05B Healthcare Drug Manufacturers - Specialty & Generic 92.68% 104.13% United Therapeutics
UTHR13.63B Healthcare Drug Manufacturers - Specialty & Generic -2.45% 39.52% Neurocrine
NBIX13.05B Healthcare Drug Manufacturers - Specialty & Generic -8.35% 24.21% Viatris
VTRS12.46B Healthcare Drug Manufacturers - Specialty & Generic -9.01% 0.38% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Zoetis Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Zoetis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 52.77%, the Debt to Equity ratio from the most recent quarter is 137.01, and its Gross Profit Margin stands at 73.62%.
- What is the recent revenue and earnings growth for ZTS?
- Looking at Zoetis's growth, its revenue over the trailing twelve months (TTM) was $9B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.20%, and quarterly earnings saw a YoY growth of 15.10%.
- How much of ZTS stock is held by insiders and institutions?
- Wondering who owns Zoetis stock? Company insiders (like executives and directors) hold about 0.09% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 98.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.